Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
19 Results for "
BRD4-IN-3
" in MedChemExpress (MCE) Product Catalog:
Products (19)
19 Results for "BRD4-IN-3" in MCE Product Catalog:
Cat. No.: HY-104072
CAS No.: 1380087-86-4
Target:
Research Areas:
BRD4-IN-3 (compound 141) is a potent BRD4 inhibitor with an IC50 of <0.5 µM. BRD4-IN-3 shows cytoxicity for MYC-Raji with an IC50 value of >1 µM .
1
1 Cited Publications
Cat. No.: HY-160528
IBG3 is a bivalent molecular glue degrader that targets BRD2 and BRD4, with an EC50 of 32 nM and a Kd of 0.6 µM against human BRD4. IBG3 exhibits selectivity for BRD2 and BRD4 over BRD3. By recruiting the DCAF16 E3 ligase, IBG3 cis-binds to the tandem bromodomains of BRD2 and BRD4, enhances BRD-DCAF16 binding affinity, promotes ubiquitination and proteasomal degradation, and does not degrade isolated bromodomains. IBG3 lacks degradation selectivity for PSMA-positive and PSMA-negative prostate cancer cells, but shows lower in vivo antitumor efficacy than the PSMA-targeting conjugate IBG-P3, and can be used in prostate cancer-related research .
Research Areas:
BRD4 degrader-3 is a molecular glue degrader targeting BRD4, with binding activity towards the BD1 and BD2 domains of BRD4. BRD4 degrader-3 regulates the activity of BRD4. BRD4 degrader-3 inhibits MYC expression in cancer cells. BRD4 degrader-3 suppresses cell proliferation. BRD4 degrader-3 can be used in research related to acute myeloid leukemia and prostate cancer .
Synonyms: TEN-010
Target:
Research Areas:
(S)-JQ-35 (TEN-010) is an orally active, blood-brain barrier-permeable bromodomain inhibitor that selectively targets the bromodomain and extra-terminal domain (BET) protein family (BRD4, BRD3, BRD2 and BRDT). (S)-JQ-35 blocks the activation of Myc gene expression by BRD4, thereby inhibiting cancer cell proliferation and promoting cancer cell apoptosis. (S)-JQ-35 can be used in research related to NUT midline carcinoma and neuroblastoma .
Cat. No.: HY-160558
CAS No.: 2251709-91-6
Research Areas:
PLK1/BRD4-IN-3 (Compound 21) is a selective dual inhibitor for bromodomain 4 (BRD4) and polo-like kinase 1 (PLK1). PLK1/BRD4-IN-3 inhibits BRD4-BD1, PLK1 and BRDT-BD1, with IC50s of 0.059, 0.127 and 0.245 μM, respectively .
Cat. No.: HY-174210
Target:
Research Areas:
PROTAC BRD4 Degrader-3 is a potent BRD4 PROTAC degrader with DC50 values of 164 nM and 80 nM at 4 h and 24 h, respectively. PROTAC BRD4 Degrader-3 induces the ubiquitination and subsequent proteasomal degradation of BRD4 by recruiting the ubiquitin E3 ligase KLHDC2. PROTAC BRD4 Degrader-3 can be used in breast cancer research .
Cat. No.: HY-139620
CAS No.: 2762181-19-9
Target:
Research Areas:
MS83 is a selective degrader of BRD4/BRD3 belonging to the PROTAC class. MS83 hijacks the KEAP1-dependent CUL3 ligase complex by binding to KEAP1 and forming a ternary complex with BRD4/BRD3. MS83 induces polyubiquitination and degradation of BRD4/BRD3 in a concentration-, time- and ubiquitin-proteasome system-dependent manner. MS83 inhibits c-MYC protein levels and suppresses the proliferation of triple-negative breast cancer cells .
Cat. No.: HY-169170
Research Areas:
PARP1/BRD4-IN-3 (compound HF4) is a potent BRD4 and PARP1 inhibitor with IC50 values of 1210, 2019 nM for BRD4, PARP1, respectively. PARP1/BRD4-IN-3 shows antiproliferative activities. PARP1/BRD4-IN-3 induces apoptosis and cell cycle arrest at G0/G1 phase. PARP1/BRD4-IN-3 causes DNA damage and reduces the protein expression of Rad51. PARP1/BRD4-IN-3 shows antitumor efficacy .
Cat. No.: HY-135558
CAS No.: 2313234-00-1
Target:
Research Areas:
PROTAC BRD4 Degrader-3 is a VHL-recruiting PROTAC degrader that targets BRD4. PROTAC BRD4 Degrader-3 consists of a VHL E3 ubiquitin ligase ligand and a BRD4 inhibitor linked by a connector .
Cat. No.: HY-149948
Target:
Research Areas:
PROTAC BRD3/BRD4-L degrader-2 is a PROTAC molecule and can selectively degrade cellular BRD3 and BRD4-L with Ki values of 16.91 and 2.8 nM, respectively. PROTAC BRD3/BRD4-L degrader-2 also has robust antitumor activity in mouse xenograft models. PROTAC BRD3/BRD4-L degrader-2 can be used for the research of cancer .
Cat. No.: HY-176035
Target:
Research Areas:
MS479 is a PROTAC degrader targeting BRD4, BRD3 and BRD2. MS479 recruits the E3 ligase SPOP by bridging the protein GLP, thereby promoting polyubiquitination modification and subsequent 26S proteasomal degradation. MS479 inhibits the proliferation of colorectal cancer cells and can be used for research on colorectal cancer and triple-negative breast cancer .
Cat. No.: HY-174975
Target:
Research Areas:
JY-21 is a BRD4 PROTAC degrader active against both long and short BRD4 isoforms. JY-21 binds to TRIM28, RACK1, LMO7 and FUS to induce proteasomal degradation of BRD4 isoforms (DC50: 5.944 μM for long BRD4 isoform; 3.797 μM for short BRD4 isoform). JY-21 is applicable to research related to triple-negative breast cancer .
Cat. No.: HY-162876
CAS No.: 1445994-28-4
Research Areas:
PROTAC BRD4 ligand-3 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). PROTAC BRD4 ligand-3 can be used for synthesis PROTAC BRD4 Degrader-27 (HY-162875) .
Cat. No.: HY-155371
CAS No.: 3032848-64-6
Research Areas:
BT-PROTAC is a bioorthogonally activatable BRD4/BRD3 PROTAC degrader prodrug. BT-PROTAC is inactive when present alone, but upon activation by tetrazine compounds, it promotes the degradation of BRD4 and BRD3 via the ubiquitin-proteasome system, inhibits c-Myc expression, activates caspase-3, and induces apoptosis in breast cancer cells. BT-PROTAC can be used for breast cancer research .
Cat. No.: HY-175924
CAS No.: 3075063-28-1
Research Areas:
BRD3/BRD4-L ligand-2 is a BRD3/BRD4-L ligand. BRD3/BRD4-L ligand-2 serves as a ligand for the target protein in the design and development of PROTAC BRD3/BRD4-L degraders, such as PROTAC BRD3/BRD4-L degrader-2 (HY-149948). BRD3/BRD4-L ligand-2 can be used in cancer research .
Cat. No.: HY-181976
Research Areas:
dHTC3 is a selective BRD4 molecular glue degrader. dHTC3 selectively binds to BRD4 BD1 to form a BRD4-dHTC3 complex, which cooperatively recruits the SCF FBXO3 E3 ubiquitin ligase and mediates the degradation of BRD4 via the ubiquitin-proteasome pathway. dHTC3 induces proteasome- and CRL-dependent BRD4 degradation with no hook effect. dHTC3 can be used in related research on acute myeloid leukemia .
Cat. No.: HY-184670
CAS No.: 2313230-74-7
Target:
Research Areas:
VHL Ligand 8 is a von Hippel-Lindau (VHL) protein ligand. VHL Ligand 8 can be used in PROTAC synthesis-related research, such as for the synthesis of PROTAC BRD4 Degrader-3 (HY-135558) .
Cat. No.: HY-181189
CAS No.: 2412988-53-3
Research Areas:
Lenalidomide-C7-NH2 is a synthetic E3 ligase ligand-connector conjugate that can be used for the synthesis of PROTACs, such as GXF-111 (HY-153414). GXF-111 is a BRD3/BRD4-L PROTAC degrader with anti-tumor activity .
Cat. No.: HY-184671
CAS No.: 2313233-96-2
Research Areas:
VHL Ligand 41-CO-C10-NH2 is an E3 ligase ligand-linker conjugate for PROTAC synthesis. VHL Ligand 41-CO-C10-NH2 is the E3 ligase ligand-linker conjugate moiety of PROTAC BRD4 Degrader-3 (HY-135558) .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
